Your shopping cart is empty
Subscriber login
REGISTER FOR FREE EZINES
Advanced Search
- Please Select -
Regulation
Business Development
Drug Manufacturing
Device Manufacturing
Quality Management
Home
Books
Conferences
DVDs
Newsletters
Form 483
s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us
Check out our free and informative ezines and sign up now
Sign Up
Home
>
Newsletters
>
FDAnews Drug Daily Bulletin
> Sanofi’s Lantus Cuts Blood Sugar More Than Merck’s Januvia
FDAnews Drug Daily Bulletin
June 12, 2012
| Vol. 9 No. 115
Sanofi’s Lantus Cuts Blood Sugar More Than Merck’s Januvia
Sanofi’s Lantus insulin reduced blood-sugar levels to a greater degree than Merck’s Januvia in people with Type 2 diabetes in a clinical trial.
The Wall Street Journal
Register Now
Print This Page
Email This Article
RSS
Archives
Related Articles
Pharma Blog Watch
Clinic Becomes Pharma-Free Through Education, Staff Input
GSK to Shut Down Tablet-Packaging Facility in Melbourne
Global Recommendations on Child Medicine